Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis.
Clin Rheumatol
; 41(7): 2213-2223, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: covidwho-1888895
ABSTRACT
OBJECTIVES:
COVID-19 pandemic has already had a tremendous impact on the process of human society; the survival of mankind and the healthy living environment deterioration with the influence will last for many years. This meta-analysis aims to assess the risk of COVID-19 in patients with rheumatic diseases.METHODS:
PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM) were systematically searched with no language restriction up to July 5, 2021. The pooled rates were synthesized by fixed effect model or random effect model depending on heterogeneity.RESULTS:
A total of 83 articles were included in this meta-analysis. The incidence of COVID-19 in patient with rheumatic diseases was 0.0190 (95% CI 0.0136-0.0252), and the hospitalization rate, intensive care unit admission rate, mechanical ventilation rate, and case fatality rate of patients with rheumatic diseases infected with COVID-19 were 0.4396 (95% CI 0.3899-0.4898), 0.0635 (95% CI 0.0453-0.0836), 0.0461 (95% CI 0.0330-0.0609), and 0.0346 (95% CI 0.0218-0.0493), respectively.CONCLUSIONS:
Our research shows that patients with rheumatic diseases have great risk of COVID-19. Differences in COVID-19 incidence, hospitalization rates, and mortality rates in regions were statistically significant. We still need to pay attention to the risk of COVID-19 in patients with rheumatic diseases. KEY POINTS ⢠Although the risk of COVID-19 in patients with rheumatic diseases has been discussed in previous meta-analysis, their research directions were inconsistent, and few studies focus on prevalence or serious outcomes of COVID-19 in patient with rheumatic diseases, while the quality of these articles was variable. ⢠The incidence of COVID-19 and serious clinical outcomes in patients with rheumatic diseases were still high along with differential risks in most regions. ⢠The use of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs did not affect the hospitalization rate and mortality in rheumatism patients with COVID-19.Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Doenças Reumáticas
/
COVID-19
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Ensaios controlados aleatorizados
/
Revisões
/
Revisão sistemática/Meta-análise
Tópicos:
Covid persistente
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin Rheumatol
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
S10067-022-06087-1
Similares
MEDLINE
...
LILACS
LIS